Concert Pharmaceuticals, Inc. (CNCE)
(Delayed Data from NSDQ)
$10.65 USD
+0.69 (6.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.67 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.65 USD
+0.69 (6.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.67 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Catalyst's (CPRX) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.
Trillium (TRIL) Soars: Stock Adds 6% in Session
by Zacks Equity Research
Trillium (TRIL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 39.71% and 63770.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Concert Pharmaceuticals (CNCE) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Concert (CNCE) Upgraded to Buy: Here's Why
by Zacks Equity Research
Concert (CNCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Concert Pharmaceuticals (CNCE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CNCE) Outperforming Other Medical Stocks This Year?
Small Drug Industry Prospects Bright Amid Coronavirus Gloom
by Kinjel Shah
Small drugmakers post impressive first-quarter results. Though second-quarter results may be severely impacted by the coronavirus pandemic, an improvement is expected in the second half.
How Concert Pharmaceuticals (CNCE) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Catalyst (CPRX) beats on Q1 earnings but misses on revenues. It also withdraws sales guidance due to the coronavirus pandemic.
Concert Pharmaceuticals (CNCE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 5.41% and -65.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Concert (CNCE) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Concert (CNCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Concert Pharmaceuticals (CNCE) Stock Might be a Great Pick
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 15.29% and -97.14%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Concert Pharmaceuticals (CNCE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 15.22% and -83.67%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
by Zacks Equity Research
Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.
Earnings Preview: Concert Pharmaceuticals (CNCE) Q1 Earnings Expected to Decline
by Zacks Equity Research
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Concert Pharma Initiates Early-Stage Schizophrenia Study
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) announces initiation of multiple-ascending dose phase I study to evaluate its pipeline candidate, CTP-692, as an adjunctive treatment for schizophrenia.
New Strong Sell Stocks for March 25th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for March 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed
by Zacks Equity Research
Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-445 plus tezacaftor and ivacaftor meet the primary endpoint. The company delays filing for U.S. approval.
Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed
by Zacks Equity Research
Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-659 plus tezacaftor and ivacaftor meet the primary endpoint. Stock rises almost 5%.
Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of -19.35% and -45.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 8.06% and -90.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval
by Zacks Equity Research
Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.